PASADENA, Calif., Feb. 18 /PRNewswire-FirstCall/ -- AutoImmune Inc. (Nasdaq: AIMM) today announced that its joint venture with Deseret Laboratories International has begun direct sales of Colloral(R), a product for the nutritional support of patients with rheumatoid arthritis. The new product can be purchased over the internet at ColloralLLC.com or by contacting Colloral LLC at 1414 East 3850 South, St. George, UT 84790 (toll free 1-877-284-7246).

Robert C. Bishop, Ph.D., Chairman of the Board and Chief Executive Officer, stated "Colloral(R) has undergone extensive clinical testing which demonstrated its unique formulation of undenatured Type II collegen to be remarkably safe and of substantial benefit to a large number of patients." All of the development work on Colloral(R) was done under IND's by AutoImmune and its collaborators who originally anticipated marketing the product as a pharmaceutical. The company transitioned the product to the nutritional supplement category by filing a "Notice of New Dietary Ingredient" with the FDA.

AutoImmune is a biopharmaceutical company involved in the development of a new class of mucosally administered therapies for the treatment of autoimmune and cell-mediated inflammatory diseases and conditions.

This release contained forward-looking statements which involve risks and uncertainties. The Company's actual results may differ significantly from results discussed in the forward-looking statements due to a number of important factors, including, but not limited to the uncertainties of clinical trial results, the Company's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission in the section "Business-Factors to be Considered." The discussion in the Annual Report on Form 10-K is hereby referenced into this release.